Australia markets close in 6 hours 6 minutes
  • ALL ORDS

    7,704.00
    +33.50 (+0.44%)
     
  • ASX 200

    7,431.40
    +37.10 (+0.50%)
     
  • AUD/USD

    0.7367
    +0.0004 (+0.05%)
     
  • OIL

    71.99
    +0.34 (+0.47%)
     
  • GOLD

    1,799.70
    -0.10 (-0.01%)
     
  • BTC-AUD

    53,416.36
    +2,566.62 (+5.05%)
     
  • CMC Crypto 200

    925.29
    +49.06 (+5.60%)
     
  • AUD/EUR

    0.6228
    +0.0002 (+0.04%)
     
  • AUD/NZD

    1.0581
    +0.0009 (+0.09%)
     
  • NZX 50

    12,616.39
    +26.08 (+0.21%)
     
  • NASDAQ

    14,956.97
    -168.98 (-1.12%)
     
  • FTSE

    6,996.08
    -29.35 (-0.42%)
     
  • Dow Jones

    35,058.52
    -85.79 (-0.24%)
     
  • DAX

    15,519.13
    -99.85 (-0.64%)
     
  • Hang Seng

    25,086.43
    -1,105.89 (-4.22%)
     
  • NIKKEI 225

    27,970.22
    0.00 (0.00%)
     

UPDATE 1-Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

(Adds details on agreement, background)

June 17 (Reuters) - Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.

Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said.

They would jointly develop and market the drug, MORAb-202, in Asia, Europe, the United States and Canada.

Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.

The drugmaker has been betting on sales of its Opdivo drug to treat such cancers, in a market currently dominated by Merck & Co's rival treatment, Keytruda.

Eisai's drug, MORAb-202, is being developed for the treatment of solid tumors, including ovarian, lung and breast cancers and is in the early stage of development.

Bristol-Myers will pay Eisai a royalty on sales outside of the collaboration territories, the companies said.

(Reporting by Amruta Khandekar; Editing by Vinay Dwivedi)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting